Skip to main content

Table 1 Inclusion criteria of iGeLU study

From: Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study)

1

Age 18–65 years, male or female

2

Diagnosed as active lupus nephritis (meet the following three standards at the same time):

a Participants fulfill the SLE classification criteria by the American College of Rheumatology (ACR) in 2009.

b Proteinuria of no less than 1.0 g/24 h within the 4 weeks before enrollment, with or without microscopic hematuria.

c Active lupus nephritis confirmed by biopsy and classified as class III/IV/V type or compound type (III+V or IV+V) according to the classification of lupus nephritis within 3 months prior to screening.

3

Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2000) scores ≥ 8 points within 2 weeks before enrollment.

4

Weight no less than 40 kg.

5

The participant agrees to take measures for birth control contraception

6

The patient agrees to participate and provides informed consent